Kigelia (Kigelia africana)

Kigelia africana is an African tree whose fruit extract contains bioactive compounds that demonstrate selective anti-cancer properties in laboratory studies. The extract works by suppressing EMT markers like Snail and survivin proteins in colorectal cancer cells while showing cytotoxicity against breast cancer cell lines.

Origin & History

Kigelia africana, commonly known as the sausage tree, is a tree native to continental Africa belonging to the Bignoniaceae family, with medicinal parts primarily from its fruits, leaves, and stems. The plant is sourced from wild or cultivated trees in tropical African regions, and extracts are typically prepared using solvents like methanol, hexane, or water from fruits or leaves, yielding lipidosterolic, methanolic, or polyherbal fractions.

Historical & Cultural Context

Kigelia africana has been used in African traditional medicine for centuries to treat wounds, rheumatism, psoriasis, diarrhea, stomach ailments, and male reproductive disorders. Fruits, leaves, and stems are applied topically or ingested, with emerging recognition for anticancer potential building on historical folk remedies.

Health Benefits

• May inhibit colorectal cancer cell growth - fruit extract showed 77.3% reduction in EMT marker Snail and 52.2% suppression of survivin in HT-29 cells (preliminary in vitro evidence) • Potential selective anti-breast cancer effects - demonstrated cytotoxicity in MDA-MB-231 and MCF-7 cell lines while sparing non-cancer kidney cells (preliminary in vitro evidence) • Possible neuroblastoma suppression - dose-dependent inhibition of stage 4 neuroblastoma cell proliferation observed (preliminary in vitro evidence) • Traditional wound healing support - methanolic extract at 2 μg/ml promoted healing in HaCaT/BJ cells (preliminary in vitro evidence) • Historical use for benign prostatic hyperplasia - lipidosterolic extract tested in animal models, though human evidence lacking (traditional use only)

How It Works

Kigelia fruit extract suppresses epithelial-mesenchymal transition (EMT) markers, specifically reducing Snail expression by 77.3% and survivin protein by 52.2% in colorectal cancer cells. The bioactive compounds appear to selectively target cancer cell survival pathways while sparing normal cells. The extract demonstrates cytotoxic effects against MDA-MB-231 and MCF-7 breast cancer cell lines through mechanisms that remain under investigation.

Scientific Research

No human clinical trials, RCTs, or meta-analyses were identified; all evidence is limited to preclinical in vitro studies. Key studies include evaluation of fruit extract on HT-29 colorectal carcinoma cells showing modulation of 42 oncology proteins (PMID: 41515404), selective cytotoxicity on breast cancer cell lines (PMID: 38837975), and neuroblastoma proliferation inhibition (PMID: 36029541).

Clinical Summary

Current evidence for Kigelia is limited to preliminary in vitro studies using cancer cell lines. Laboratory research showed 77.3% reduction in EMT marker Snail and 52.2% suppression of survivin in HT-29 colorectal cancer cells. Additional studies demonstrated selective cytotoxicity against MDA-MB-231 and MCF-7 breast cancer cell lines. No human clinical trials have been conducted to validate these preliminary findings or establish safety profiles.

Nutritional Profile

{"macronutrients": {"carbohydrates": "Approximately 15-20 g per 100 g of fruit", "protein": "Approximately 1-2 g per 100 g of fruit", "fiber": "Approximately 3-5 g per 100 g of fruit"}, "micronutrients": {"vitamin_C": "Approximately 30-40 mg per 100 g of fruit", "calcium": "Approximately 50-70 mg per 100 g of fruit", "potassium": "Approximately 200-250 mg per 100 g of fruit"}, "bioactive_compounds": {"iridoids": "Present in significant amounts, exact concentration varies", "flavonoids": "Present, including luteolin and quercetin derivatives", "naphthoquinones": "Lawsone and related compounds present"}, "bioavailability_notes": "Nutrient absorption may be influenced by the presence of anti-nutritional factors such as tannins and oxalates, which can bind minerals and reduce their bioavailability."}

Preparation & Dosage

No clinically studied dosages in humans are available. In vitro studies used various concentrations achieving cytotoxicity in cancer cell lines, with methanolic extract at 2 μg/ml for wound healing applications. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Cisplatin (laboratory synergy noted), African potato, Pygeum, Saw palmetto, Beta-sitosterol

Safety & Interactions

Safety data for Kigelia supplementation is extremely limited due to lack of human studies. Traditional use suggests general tolerability, but no formal toxicity studies have established safe dosage ranges. Potential interactions with chemotherapy drugs or hormone-sensitive medications are unknown and require medical supervision. Pregnancy and breastfeeding safety has not been established, making use inadvisable during these periods.